Histamine: A Novel Approach to Cancer Immunotherapy

Abstract

The functions of intratumoral lymphocytes in many human malignant tumors are inhibited by reactive oxygen species (ROS), generated by adjacent monocytes/macrophages (MO). In vitro data suggest that immunotherapeutic cytokines such as interleukin-2 (IL-2) or interferon-α (IFN-α) only weakly activate T cells or natural killer (NK) cells in a reconstituted environment of oxidative stress and that inhibitors of the formation of ROS or scavengers of ROS synergize with IL-2 and IFN-α to activate T cells and NK cells. In this review, we focus on the immunoenhancing properties ofhistamine, a biogenic amine. Histamine inhibits ROS formation in MO via H2–receptors; thereby, histamine protects NK cells from MO-mediated inhibition and synergizes with IL-2 and IFN-α to induce killing of NK cell-sensitive human tumor cells in vitro. Histamine also optimizes cytokine-induced activation of several subsets of T cells by affording protection against MO-inflicted oxidative inhibition. The putative clinical benefit of histamine as an adjunct to immunotherapy with IL-2 and/or IFN-α is currently evaluated in clinical trials in metastatic malignant melanoma and acute myelogenous leukemia.